The LG AI Research lab, part of the South Korean LG Group, has introduced the upgraded artificial intelligence model EXAONE Path 2.0 aimed at pathology research.
This was reported by Yonhap.
The lab explained that compared to its predecessor, EXAONE Path 2.0 significantly improves accuracy in analyzing and predicting genetic mutations, gene expression patterns, and minor structural changes in human cells and tissues through pathological image analysis.
Notably, the model was trained on over 10,000 datasets covering visualization and multi-omics, allowing it to predict gene activity solely based on image analysis without the need for costly genomic testing.
“Thanks to EXAONE Path 2.0, genetic testing can be completed in under a minute compared to more than two weeks previously required. This will help save critical time in treating cancer patients,” said the lead researcher at LG AI Research, Park Yong-min.
He added that doctors and pharmaceutical companies can utilize EXAONE Path 2.0 for rapid analysis of pathological images in oncology patients, identifying genetic mutations and selecting appropriate targeted therapies.
As previously reported by Ukrinform, the Chinese company DeepSeek introduced an updated AI-based model DeepSeek R1, thus intensifying its competition with OpenAI, the developer of the popular chatbot ChatGPT.
